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Lior Epstein 3,4,5, Mirta Dumančić 3, Sara Del Mare 1, Amit Shai 1,
Michael Schmidt 6, Lisa Deutsch 7, Robert B. Den 1,8,
Itzhak Kelson 9, Yona Keisari 10, Lior Arazi 3*‡, Tomer Cooks 2*‡
and Vered Domankevich 1*‡
1
Translational Research Laboratory, Alpha Tau Medical, Jerusalem, Israel, 2 The Shraga Segal
Department of Microbiology, Immunology and Genetics, Faculty of Health Sciences, Ben-Gurion
University, Beer-Sheva, Israel, 3 Unit of Nuclear Engineering, Faculty of Engineering Sciences, BenGurion University of the Negev, Beer-Sheva, Israel, 4 Radiation Protection Department, Soreq
Nuclear Research Center, Yavne, Israel, 5 Department of Biomedical Engineering, Faculty of
Engineering, Tel Aviv University, Tel Aviv, Israel, 6 Physics Laboratory, Alpha Tau Medical,
Jerusalem, Israel, 7 Biostatistics Department, BioStats Statistical Consulting Ltd., Maccabim, Israel,
8
Department of Radiation Oncology, Urology, and Cancer Biology, Thomas Jefferson University,
Philadelphia, PA, United States, 9 School of Physics and Astronomy, Raymond and Beverly Sackler
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Glioblastoma multiforme (GBM) is at present an incurable disease with a 5-year
survival rate of 5.5%, despite improvements in treatment modalities such as
surgery, radiation therapy, chemotherapy [e.g., temozolomide (TMZ)], and
targeted therapy [e.g., the antiangiogenic agent bevacizumab (BEV)].
Diffusing alpha-emitters radiation therapy (DaRT) is a new modality that
employs radium-224-loaded seeds that disperse alpha-emitting atoms inside
the tumor. This treatment was shown to be effective in mice bearing humanderived GBM tumors. Here, the effect of DaRT in combination with standardof-care therapies such as TMZ or BEV was investigated. In a viability assay, the
combination of alpha radiation with TMZ doubled the cytotoxic effect of each
of the treatments alone in U87 cultured cells. A colony formation assay
demonstrated that the surviving fraction of U87 cells treated by TMZ in
combination with alpha irradiation was lower than was achieved by alpha- or
x-ray irradiation as monotherapies, or by x-ray combined with TMZ. The
treatment of U87-bearing mice with DaRT and TMZ delayed tumor
development more than the monotherapies. Unlike other radiation types,
alpha radiation did not increase VEGF secretion from U87 cells in culture.
BEV treatment introduced several days after DaRT implantation improved
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tumor control, compared to BEV or DaRT as monotherapies. The combination
was also shown to be superior when starting BEV administration prior to DaRT
implantation in large tumors relative to the seed size. BEV induced a decrease in
CD31 staining under DaRT treatment, increased the diffusive spread of 224Ra
progeny atoms in the tumor tissue, and decreased their clearance from the
tumor through the blood. Taken together, the combinations of DaRT with
standard-of-care chemotherapy or antiangiogenic therapy are promising
approaches, which may improve the treatment of GBM patients.
KEYWORDS

radiotheapy, alpha particle, antiangiogeic therapy, glioblasoma multiforme,
alpha DaRT

followed by a reduction in vessel density and blood ﬂow (11),
which induces a metabolic switch towards anaerobic glycolysis
(6) and increased cell invasion (11). Notably, VEGF was
reported to be upregulated upon low linear energy transfer
(LET) irradiation (12–14), as demonstrated in different glioma
cell lines and human xenografts (6), and the involvement of
transactivating factors, such as HIF-1, was suggested (15).
Therefore, low-LET radiation therapies may disturb BEV
function by leading to an excess of VEGF relative to the
amount of available VEGF antibodies. Little is known about
the effect of high-LET radiation on VEGF secretion.
The combination of TMZ with different qualities of
radiation was previously investigated in U87 cells, showing
that the relative biological effectiveness (RBEs) of the
combined treatment increases with LET. The DNA damage
induced by alpha particles was more severe than by x-rays or
protons, as evidenced by a slower rate of disappearance of DNA
damage foci after irradiation (16). Alpha particles are widely
known to have a high cytotoxic effect (17), which is largely
insensitive to the oxygenation state of the cell (18), and is
mediated by the creation of clustered, difﬁcult-to-repair,
double-strand breaks (DSBs) through direct ionization (19,
20). The short range of alpha particles (~40–90 mm in tissue)
can further minimize collateral damage if an effective delivery
scheme is used to bring the alpha-emitting atoms to the
immediate vicinity of the cancer cells.
Recent advances in nuclear medicine opened novel avenues
for alpha particle-based treatments (21–23). These employ
antibodies, peptides, small molecules, and nano- or microparticles carrying alpha-emitting atoms, which are injected
either locally or systemically and target cancer cells. Recently,
efforts in this ﬁeld have also been directed towards recurrent
GBM management (24–26). Targeted alpha therapy (TAT)
using molecular vectors labeled by 213Bi, 211At, and 225Ac,
delivered by intracavity or intratumoral injection, have proven
to be safe and well-tolerated by GBM patients with a potential

Introduction
Glioblastoma multiforme (GBM) is the most common and
aggressive malignant primary brain tumor (1). The standard
treatment for newly diagnosed GBM patients includes surgical
resection, followed by radiation therapy and chemotherapy using
temozolomide (TMZ) (2, 3). Despite improvement in overall
survival offered by this regime, the prognosis of GBM patients
remains poor (4) and virtually all GBM tumors relapse (5).
Various strategies are investigated for treating primary and
recurrent GBM patients. One approach involves targeted
therapy with the humanized vascular endothelial growth factor
(VEGF) monoclonal antibody bevacizumab (BEV), which is
already approved for clinical use for recurrent GBM (3).
Glioma cells are a major source of VEGF (6), a key mediator
of angiogenesis (7) that correlates with malignancy grade and
poor prognosis (6). The use of BEV disrupts angiogenesis. When
employed in combination with chemotherapy and radiation
therapy, this can improve the tumor response by reducing
hypoxia and assisting drug delivery, which is otherwise
precluded by the disorganized architecture of the tumor
vascular system (6). This is especially important in GBM,
where—as a baseline—the blood–brain barrier (BBB) in itself
reduces drug delivery dramatically (e.g., only 30% of plasma
TMZ passes the BBB) (8). BEV has indeed been shown to
improve progression-free survival and performance status in
patients with GBM, but this does not translate into an overall
survival beneﬁt (9, 10). It was suggested that treatment by BEV
initially decreases tumor hypoxia and reduces tumor edema,
during a transient normalization phase (6), but that this effect is

Abbreviations: GBM, Glioblastoma multiforme; DaRT, Diffusing alphaemitters radiation therapy; TMZ, Temozolomide; BEV, Bevacizumab;
VEGF, Vascular endothelial growth factor; LET, Linear energy transfer.
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by stimulating an immune response (42–45). This was
successfully translated into a clinical trial of recurrent and
locally advanced squamous cell carcinoma of the skin and
head and neck, in which the DaRT treatment achieved a 100%
tumor response (with all tumors shrinking by 30%–100%), with
78.6% complete response (macroscopic disappearance) of the
tumors, and with minimal adverse effects (46). The calculated
kidney and red bone marrow dose in all patients was on the cGy
level, with no signs of systemic toxicity. Preclinical studies have
also demonstrated the superiority of DaRT when combined with
chemotherapy in squamous cell carcinoma (40), pancreatic (33),
and colon cancer xenograft models (38). Yet, in GBM xenografts,
the effect of DaRT was only investigated as a monotherapy (39)
and the effective inhibition of tumor development was not
conducted with the standard clinical care of GBM, an essential
step for translating the preclinical results into clinical therapy.
In the context of treating recurrent GBM, DaRT has the
potential advantage of allowing for controlled geometrical
coverage of the tumor volume, by the use of dedicated
applicators that enable the insertion of multiple seeds from a
single entry point. With each seed creating a well-deﬁned, highdose region in its few-millimeter vicinity, this approach can
permit quantitative treatment planning, as well as real-time
identiﬁcation of potential cold spots and their mitigation.
Unlike intratumoral injection [of either TAT vectors, or
vehicles carrying beta emitters such as 186Re (47) or 90Y (48)],
which is subject to uncertainty resulting from uncontrolled
pressure gradients and backﬂow, the single-atom diffusion
process in DaRT (in particular, that of 220 Rn) is more
predictable and less prone to inadvertent local toxicity. While
the diffusing atoms do not bind speciﬁcally to cancer cells as in
TAT, their continuous distribution in the seed vicinity and the
rapid fall-off of the dose outside of the treatment region can be
regarded as “geometric targeting”. Compared to interstitial
treatments for using 125I (49) or 192Ir (50), which also provide
controlled geometric coverage of the target volume, the use of
alpha particles in DaRT is immune to hypoxia, and the rapid
fall-off of the dose is expected to lead to reduced toxicity to
normal brain tissue. Lastly, the production of the 224Ra-loaded
DaRT seeds relies on thorium-228 (228Th), which is readily
available at large quantities and has a half-life of 1.9 years,
allowing for a steady, cost-effective, and large-scale
manufacturing of seeds.
In the current study, we investigated the potential of DaRT
in combination with BEV or TMZ to eradicate GBM xenografts.
In addition, the cytotoxicity of alpha radiation in combination
with TMZ and the effect of alpha radiation on VEGF secretion
by U87 cells were studied in vitro. Finally, we also studied the
effect of BEV on the diameter of the high-dose region
surrounding the DaRT seed and on the rate of 212Pb clearance

positive effect on overall survival. Recent clinical trials showed
potential therapeutic efﬁcacy and minor side effects, thus
opening a promising era for GBM medical care (27–30).
Challenges remain, however, in developing catheter systems
that will allow for effective coverage of the entire tumor
volume while minimizing unwanted backﬂow or spillage into
regions of normal brain tissue. In addition, further
improvements are desirable in the chemical and biological
properties of the molecular vectors carrying the alpha emitters,
in terms of stability, speciﬁcity to cancer cells, and ability to
diffuse freely inside the tumor.
In this work, we consider the combination of TMZ and BEV
with another modality using alpha particles: diffusing alphaemitters radiation therapy (DaRT). DaRT is a unique method
that allows the treatment of solid tumors by alpha particles using
implantable sources (“seeds”) carrying low activity levels of
224
Ra (t1/2 = 3.63 days) a few nanometers below their surface
(31, 32). Once inside the tumor, the DaRT seed continuously
releases radon-220 (220Rn, t1/2 = 55.6s) atoms by recoil into the
tumor tissue. The process continues as long as the seed remains
inside the tumor, and its rate decays exponentially with the halflife of 224Ra, such that ~75% of the total dose is delivered within
the ﬁrst week, and ~95% in 16 days. 220Rn, a noble gas, diffuses
freely as a free atom in the vicinity of the seed, decaying by alpha
emission (Ea = 6.29 MeV) up to ~2–3 mm away from its surface,
followed by additional alpha emissions by 216Po (t1/2 = 0.145s,
Ea = 6.78 MeV) at the same location, and by the alpha-emitting
daughters of 212Pb (t1/2 = 10.64h) − 212Bi (t1/2 = 60.55min, Eā =
6.06 MeV) and 212Po (t1/2 = 0.30ms, Ea = 8.78 MeV). The
diffusion process creates a continuous “kill region” of a
therapeutic alpha-particle dose (̴ 10–20 Gy) with a typical
diameter of ~3–5 mm, for a seed carrying a few microcurie of
224
Ra (31, 33). This suggests positioning seeds at a spacing of a
few millimeters from each other. The effective diameter of the
high-dose region around the seed depends on the tumor type
and is thought to be affected by the presence of active vasculature
and necrotic domains (32). When treating the tumor with an
array of seeds, the dose falls off to negligible levels ~2–3 mm
away from the outermost seeds (34, 35). 212Pb atoms entering
the bloodstream are trapped by red blood cells (31, 36) and may
thus “leak” out from the tumor, with subsequent uptake in
various organs. Estimates from a biokinetic model, based on the
lead and bismuth models of the International Commission on
Radiological Protection (ICRP), indicate that the maximal
tolerable activity of 224Ra on the DaRT seeds, limited by the
dose to the kidneys and red bone marrow, is a few
millicurie (36).
Preclinical studies have demonstrated the capabilities of
DaRT to produce in vivo anti-tumor responses in multiple
tumor-bearing mice models (31, 33, 37–41) both directly, and
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from the tumor. The results of this study are a ﬁrst step in
investigating the potential use of DaRT in combination with
TMZ and/or BEV in the treatment of recurrent GBM.

adhesive, MED2-4213), which allows 220 Rn atoms to be
released into the tumor tissue. The 220 Rn desorption
probability (the probability that a 220Rn atom is emitted from
the seed following a decay of 224Ra) was 40%–45%, unless
mentioned otherwise. The 224Ra activity was 2 or 3 mCi (~75
or 110 kBq). Seeds, either loaded with 224Ra or inert, were placed
near the tip of a 19- or 18-gauge needle connected to a seed
insertion applicator (essentially a modiﬁed syringe, see Figure 2).
A single radioactive or inert seed was inserted into the tumor
under anesthesia (xylazine 10 mg/kg, ketamine 100 mg/kg).

Materials and methods
Animals
All animal experiments were carried out in accordance with
the government and institution guidelines and regulations
(Ethics approval 01-20-055, IL-80-10-2020E) and with the
National Institute of Health Guide for the Care and Use of
Laboratory Animals (NIH Publications No. 8023, revised 1978).
Athymic nude mice, strain Hsd: Athymic-Nude-Foxn1-nu
female mice (24–30 g, 12–15 weeks) were obtained from
Envigo (Jerusalem, Israel) and kept in the animal facility of
Tel Aviv University or Ben-Gurion University.

Drug preparation and storage
TMZ (cat. # S1237, Selleckchem, TX, USA) was dissolved in
DMSO and prepared in aliquots of 20 mg/ml DMSO. Stock
solution was stored at −80°C. A solution of BEV at 4 mg/ml
(Avastin® Genentech, CA, USA) was stored at 2–8°C in a
refrigerator in the dark. Control antibody human IgG1 (Sigma,
MO, USA, cat. # I4506) was stored prior to reconstitution
at 2–8°C. After reconstitution, aliquots were stored at –20°C.

Tumor cell lines
U87 human GBM cell line (ATCC) cells were grown in
MEM-NEAA containing L-glutamine (Cat. # 01-040-1A,
Biological Industries, Kibbutz Beit Haemek, Israel),
supplemented with 10% non-heating inactivated fetal calf
serum, penicillin (100 U/ml), and streptomycin (100 mg/ml)
(Biological Industries, Kibbutz Beit Haemek, Israel), in a humid
incubator at a temperature of 37°C and 5% CO2.

In vivo drug treatments
For the in vivo studies, TMZ was dissolved in 5% DMSO and
30% PEG300 in ddH2O (51), and 200 µl of 1 mg/kg TMZ was
injected i.p. into the mice; 5% DMSO and 30% PEG300 in
ddH2O was used as a vehicle control. Treatment started 1 day
after DaRT insertion (day 0) for a total of nine doses (days 1–4
and 6–10). BEV (5 mg/kg) was administrated i.p. at 90–130 µl/
mouse, starting from day 5 after DaRT insertion (on days 5, 7, 9,
12, 14, 16, 19, 21, and 23, where day 0 is the day of DaRT seed
insertion) unless mentioned otherwise in the Results section.

Tumor cell inoculation
U87 cells were inoculated intracutaneously to the right lower
lateral side of the back in a concentration of 5 × 106 cells/100 ml
of HBSS (Biological Industries, Kibbutz Beit Haemek, Israel),
using a 29-gauge needle. The procedure was performed under
anesthesia (xylazine 10 mg/kg, ketamine 100 mg/kg, i.p.(or
isoﬂurane (5% isoﬂurane for initial anesthesia and 3%
isoﬂurane for the DaRT insertion procedure).

In vivo tumor measurements
Local tumor growth was determined two to three times per
week after seed insertion by measuring three mutually
orthogonal tumor diameters (D1, D2, D3) using a digital
caliper, along with radioactivity measurement using a Geiger
counter to conﬁrm the presence of a DaRT seed in the tumor.
Tumor volume was estimated as p6 D1 D2 D3 . Animal welfare was
monitored (body weight measurements and animal behavior)
and survival was recorded on the day of tumor measurements.
Animals were sacriﬁced and considered dead on the day the
tumor size reached the ethical limit (1,500 mm3 for BEV
experiments or 15 mm for TMZ experiment). The experiments
were terminated when in all groups at least one animal died,
unless mentioned otherwise.

DaRT seeds preparation and insertion
DaRT seeds were made of 6.5-mm-long stainless steel (316
LVM) tubes with an outer diameter of 0.7 mm and an inner
diameter of 0.4 mm, loaded with 224Ra atoms, following an
electrostatic collection process similar to that described in (31).
To prevent radium detachment from the surface, the seeds were
subsequently coated by a 1-mm-thick biocompatible polymer
layer made from polydimethylsiloxane (PDMS-silicone
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In vitro irradiation setups

In vitro treatment for viability assay

U87 cells were exposed in vitro to alpha particles with and
without TMZ in a viability assay, and to both alpha particles and
x-rays, with and without TMZ, in a colony formation assay. In
vitro exposure to alpha particles was done in irradiation stations
(“Kapton wells”, Figure 1A), each equipped with a 3.8-mCi (140
kBq) 241Am source, which, due to partial screening, had an alpha
emission rate of 50 ± 2.5 kHz. Cells were seeded on a 7.5-mm
thick Kapton foil (polyamide ﬁlm PRN-IF70, Pornat, Israel)
assembled between two cylindrical stainless steel parts with an
exposed area 9 mm in diameter, as previously described (52).
The cells, covered by a medium, were positioned 9.6 mm above
the 241Am source in air and exposed to a controlled ﬂux of alpha
particles, at an average dose rate of 0.10 Gy/min. The dose rate
was estimated by measuring the spectrum and emission rate of
alpha particles from the 241Am source with an alpha-particle
spectrometry system, supplemented by a Monte Carlo
simulation of the full setup, using a dedicated MATLAB script
utilizing SRIM 2013 (53). The calculated mean alpha-particle
energy, when passing through the cell layer, was 2.7 MeV, with
an LET of 130 ± 3 keV/mm (where the variations reﬂect the
radial position across the foil). For x-ray exposure, cells were
seeded in six-well plates and irradiated with a Faxitron cabinet xray system MultiRad 160 (Faxitron X-ray Corporation, IL, USA).

Cells were seeded in the Kapton wells in ﬁve replicates for
each treatment. Twenty-four hours post seeding, the medium
was replaced by a fresh complete medium or by a complete
medium containing 300 µM TMZ dissolved in DMSO, or DMSO
as control (54). The TMZ concentration and alpha dose were
pre-calibrated and chosen to achieve 80% viability following
monotherapies. Exposure to alpha particles at a single level (1.4
Gy) was performed 2 h after the medium was replaced. The cells
then remained in incubation with or without TMZ for an
additional 70 h and were then subjected to a PrestoBlue
viability assay. The experiment was repeated three times.

PrestoBlue viability assay
To evaluate cell viability, PrestoBlue reagent (A13261,
Invitrogen, CA, USA) was used as follows: The cell medium
was removed and a 240-µl phenol-red-free DMEM medium
(Biological Industries, Kibbutz Beit Haemek, Israel) containing
10% PrestoBlue was added to each Kapton well. After 30 min of
incubation, duplicates of 100 µl of medium containing
PrestoBlue from each well were transferred to a 96-well plate.
Absorbance was measured either using an EMax Plus microplate

A

B

C

FIGURE 1

Cytotoxic effect of alpha and x-ray radiation, TMZ, or the combined treatment on U87 cells. (A) Alpha irradiation setup. Cells were seeded on a
Kapton foil and exposed to alpha particles emitted by a 241Am source placed, in air, 9.6 mm below. (B) The effect of 1.4 Gy of alpha particles,
300 µM TMZ (72 h), or the combination of the two. Cytotoxicity is calculated as the difference between viability following treatment (% from
control) and that of the control (100%) and is expressed as mean ± standard deviation of three independent experiments. *pt-test<0.05,
***pt-test<0.0005. (C) Colony formation assay, with cells irradiated by alpha particles or x-rays with and without TMZ (15 µM of TMZ for 24 h
prior to irradiation).
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reader (Molecular Devices, CA, USA) at 570 and 595 nm, or a
Multiskan Spectrum spectrophotometer (Thermo Scientiﬁc,
MA, USA) at 570 and 600 nm (the latter was used in the
VEGF experiment, see below). Viability values represented the
following calculation (according to the manufacturer’s
instructions): (OD570-blank) − (OD600-blank), where OD
stands for optical density.

Autoradiography of DaRT-treated
tumors and 212Pb leakage
probability measurements
A single DaRT seed (6.5 mm length, 0.7 mm outer diameter),
carrying 3 mCi 224Ra, was inserted to the center of a mice-borne
U87 tumor 7–20 days after tumor inoculation, when the tumor
transverse diameter was ~6–0 mm. Four to ﬁve days later, the
tumor was excised (as a whole) and cut in two halves, at the
estimated location of the seed center, perpendicular to the seed
axis. The seed was then pulled out using surgical tweezers and
placed in a water-ﬁlled tube for subsequent measurement by a
well-type NaI(Tl) detector (Hidex Automatic Gamma Counter).
The tumor was kept for 1 h at −80°C. It was then taken, in dry
ice, for measurement in the same gamma counter to determine
the 212Pb activity it contains, by focusing on the 212Pb 239 keV
gamma line. The measurements of the seed and tumor activity
were used to determine the 212Pb leakage probability from the
tumor (i.e., the probability that a 212Pb atom released from the
seeds leaks out from the tumor through the blood before its
decay) following the procedure described in (31, 32).
Immediately after the gamma measurement, both halves of
the tumor were subjected to histological sectioning using a
LEICA CM 1520 cryostat (Buffalo Grove, IL, USA). Sections
were cut at 250–300 mm intervals with a thickness of 10 mm, and
were then placed on positively charged glass slides, ﬁxed with 4%
paraformaldehyde (sc-281692, Santa Cruz Biotechnology Inc.,
Dallas, Texas, USA) and rinsed twice with PBS. Typically, there
were 5–15 sections per tumor, spanning a length of 1.5–5 mm.
Shortly after their preparation, the glass slides were placed, faced
down, for a duration of 1 h, on a phosphor imaging plate
(Fujiﬁlm TR2040S) protected by a 12-mm Mylar foil and
enclosed in a light-tight casing. Alpha particles emitted from
the sections in the decays of 212Pb progeny atoms, 212Bi and
212
Po, penetrate through the foil and deposit energy in the active
layer of the phosphor imaging plate. Immediately after exposure,
the plate was read out by a phosphor-imaging scanner (Fujiﬁlm
FLA-9000).
For each tumor section, the result was a two-dimensional
intensity map, proportional to the local 212Pb activity. After
performing a deconvolution process with the known pointspread-function of the system to deblur the recorded image
(31), the intensity (in units of photo-stimulated luminescence)
was converted to 212Pb activity using suitable 212Pb calibration
samples. The local 212Pb activity was then used to provide a gross
estimate of the size of the therapeutically affected region—the
effective diameter—based on the approximate procedure
described in (31). Brieﬂy, the recorded local 212Pb activity
serves to calculate the asymptotic macroscopic dose that would
have been delivered by the alpha emissions of 212Bi and 212Po (in
local secular equilibrium with 212Pb) if the seed were to be left

Colony formation assay
In the colony formation assay, x-ray irradiation was done
at 2, 5 and 10 Gy. Alpha-particle irradiation was done at 2.8, 7,
and 14 Gy. For alpha particles, in practice, only the 2.8-Gy level
was useful, as survival at higher doses was dominated by cells
evading direct hits, artiﬁcially leading to unrealistic survival
estimates. For alpha-particle irradiation, 12,000 cells were
seeded in four to six Kapton wells for each irradiation level
and covered by 300 µl of medium. For x-ray irradiation, 1.8 ×
105 cells were seeded in two wells of a six-well plate and
covered by 2 ml of medium. One day after seeding, the
medium was changed to a fresh complete medium containing
either 15 µM TMZ or DMSO (control). Twenty-four hours
later, the medium was again replaced by fresh complete
medium to stop the TMZ treatment. Cells were immediately
exposed to alpha or x-ray radiation. Shortly after irradiation,
cells were dissociated, pooled, and seeded in different
concentrations in duplicates in six-well plates for an
incubation period of 10–15 days to allow the formation of
colonies. Colonies were then ﬁxed in methanol and stained
with crystal violet. Colonies with more than 50 cells were
counted as viable. Plating efﬁciency and survival fraction
were calculated based on three independent experiments for
alpha particles and for x-rays. Survival data for x-ray
irradiation were ﬁtted by S(D) = exp(-aD-bD2 ), and for
alpha irradiation by S(D) = exp (-D/D0) (with an additional
constant term for the combination with TMZ) using MATLAB
(MathWorks, ver. R2021B).

VEGF ELISA assay
To determine VEGF levels in cell culture-conditioned
medium, medium was collected from culture wells and frozen
72 h after treatment start. VEGF secretion was determined using
quantitative-sandwich ELISA kit (Human VEGF DuoSet ELISA,
R&D Systems, #DY293B) following manufacturer’s instructions.
Normalization of VEGF secretion was performed proportionate
to the number of cells by dividing the result of VEGF secretion
by % viability (from control) according to a PrestoBlue
viability assay.
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until the ﬁrst animal in the last group died. Time to 5-fold
change in tumor volume data are depicted by a Kaplan Meier
plot; two curves are compared with a Log-rank test with p-values
adjusted for multiple comparisons using the FDR method. For
effective diameter and leakage analysis, ANCOVA was
performed. Pearson’s correlation coefﬁcient was used to assess
correlation between effective diameter and leakage. Grubbs’ test
was used to identify outliers. A p-value< 0.05 was considered
statistically signiﬁcant. The above-mentioned analyses were
performed using SAS V9.4 (SAS Institute, Cary NC, USA). For
the difference between the means of two treatments in in vitro
and ex vivo (CD31 IHC and effective diameter) studies, a twotailed Student’s t-test was used (Excel, Microsoft).

inside the tumor indeﬁnitely (in practice, for >3 weeks), assuming
a uniform time dependence of the activity throughout the tumor
volume. By calculating the total area corresponding, in a given
tumor section, to an asymptotic 212Bi/212Po alpha dose larger
than 10 Gy, A(DBiPo > 10 Gy), the effective diameter is deﬁned by:
deff = 2[A(DBiPo > 10 Gy)/p]1/2. We stress that this parameter
should be strictly considered as a gross indicator for the spatial
spread of the alpha-emitting daughters of 224Ra inside the tumor.
The 10-Gy dose is chosen as a convenient reference for actual
therapeutic alpha-particle doses that are expected to be in the
range ~10–20 Gy.
The same histological sections measured on the imaging
plate were later stained with hematoxylin–eosin (H&E) (Gbiosciences, St Louis MO, USA) for tissue damage detection.
H&E staining was correlated with the activity distribution
measurements. The pictures were taken using a Panoramic
scanner (3D HISTECH Ltd., Budapest, Hungary).

Results
Cytotoxicity of TMZ in combination with
alpha radiation is higher than the
cytotoxicity of each treatment alone

Immunohistochemical staining
and analysis

As discussed above, the combination of alpha-particle
irradiation with TMZ was studied both in a viability assay and
in a colony formation assay, where the latter also included an
arm replacing alpha particles by x-rays. In the viability assay,
cells were either treated with 300 µM TMZ (for 72 h), exposed to
a dose of 1.4 Gy of alpha-particle ﬂux, or both. Viability scores
were calculated for each treatment relative to the untreated
control group (% from control). Cytotoxicity was expressed as
the difference between viability following treatment and that of
the control. The results are shown in Figure 1B. Both TMZ and
alpha radiation exerted a cytotoxic effect on U87 cells compared
to untreated cells (p< 0.001,<0.05, or <0.0005 for TMZ, alpha
irradiation, or the combination vs. control, respectively). No
signiﬁcant difference was observed between alpha irradiation
and TMZ treatments. The combinational treatment nearly
doubled the cytotoxicity relative to each of the treatments
alone (p< 0.05, for each monotherapy vs. combination).
In the colony formation assay, cells were exposed to 0, 2.8, 7,
and 14 Gy of alpha particles and x-rays, following 24 h of TMZ.
The results are shown in Figure 1C. As noted above, for the
alpha-particle case, only the control and 2.8 Gy points were used
in the analysis, as colony formation after exposure to 7 and 14
Gy was unrealistically high (~4% and ~3%, respectively,
compared to an expected respective survival of ⪅1% and
⪅0.01%). We suspect that this resulted from cells entering a
“sheltered” region in a peripheral gap between the Kapton foil
and stainless steel cover.
Without TMZ, the mean lethal dose for alpha particles was
estimated as D0= 1.2 ± 0.2 Gy. Compared to x-rays, this translated
to RBE10 = 1.5 ± 0.3 (i.e., at 10% survival). The addition of TMZ
reduced the surviving fraction by ~40%–50% for both x-ray and
alpha-particle irradiation.

To determine the presence and expression of CD31, slides
were dried and incubated in cold acetone for 20 min and then
washed in PBS. Staining was performed with a Leica Bond-III
Automated Stainer according to manufacturer’s instructions
using the primary antibody for CD31 (ab281583, Abcam,
dilution 1:200). The immunostaining area of CD31 was
measured using ImageJ. The red channel was separated from
blue and converted to grayscale, and the background was
subtracted. The values of the monochromatic images were
then measured and expressed as percentage of area. To
quantify the CD31 staining regions, three areas from each
section (ROIs) were selected from non-necrotic areas, and
their average was calculated per each slide. One tumor was
excluded from the analysis according to Grubb’s test.

Statistical analysis
Tumor volume over time was assessed and compared
between the groups using repeated measures analysis of
variance with false discovery rate (FDR) correction for
multiple comparisons. The cubic root transformed volume was
modeled as a function of group, day (categorical), and the day ×
group interaction with baseline volume entered as a covariate.
The model estimated means (least squares means) and
conﬁdence intervals were estimated from the interaction term
for each day per group and were back transformed to the
volume. Each experiment was analyzed until the time point at
which the ﬁrst animal died. The days for which the differences
were signiﬁcant were mentioned in the Results section and the pvalue range was presented. Tumor volume graphs included data
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signiﬁcantly different from that of the combined treatment (day
20, p< 0.0005 or p< 0.05, respectively) (Figure 2B). The time to reach
ﬁvefold of the starting tumor volume was prolonged for animals
treated with DaRT, TMZ, or the combined treatment compared to
the control group (p< 0.005, p< 0.05, p< 0.001
respectively) (Figure 2C).

DaRT combined with TMZ
delayed tumor development more than
the monotherapies
Given the observed cytotoxic effect of DaRT combined with
TMZ in cultured U87 cells, the potential of such a combination was
also tested in vivo. The number of DaRT seeds and TMZ dose were
chosen so that no complete elimination of the tumor (46) will occur
in the majority of animals following monotherapies. U87 tumor cells
were inoculated, and tumors were allowed to reach an average size of
7 mm (longest diameter) for 7 days. On day 7, a single DaRT or an
inert seed (non-radioactive control) was inserted into each tumor
(Figure 2A). One day post seed insertion, mice were administrated
with TMZ or vehicle (control) for a total of 9 doses. One animal
from the combinational group was excluded due to seed loss
between days 3 and 6. Tumor growth among DaRT (n = 9), TMZ
(n = 8), or the combined treatment (n = 7) groups was reduced when
compared to the control (n = 8) group (day 20, p< 0.005; days 13–20,
p< 0.001–0.0001; days 17–20, p< 0.0005–0.0001, respectively). The
combined treatment group showed the highest tumor development
retardation effect. No signiﬁcant difference was seen in tumor growth
between the DaRT and TMZ monotherapy groups at any time point.
Tumor growth retardation induced by DaRT or TMZ was

Alpha radiation does not affect the
secretion of VEGF from U87 cells
As mentioned in the Introduction, low-LET radiation, such as
x-ray (14), can upregulate VEGF secretion. This may result in a
reduced efﬁciency of BEV treatment when given in combination
with radiation therapy. Here, we tested whether alpha irradiation
leads to the same effect, by exposing U87 cells to alpha particles (up
to 2.8 Gy) and measuring their VEGF secretion by an ELISA assay.
Due to the cytotoxicity of the treatment, cell viability, scored by the
PrestoBlue viability assay after medium removal, was used to
normalize VEGF secretion proportionally to the number of live
cells. No signiﬁcant changes in VEGF secretion by U87 cells was
observed (p-value = 0.9, 0.7, and 0.7 for control vs. 0.7 Gy, 1.4 Gy,
and 2.8 Gy, respectively) (Table 1).

A

B

C

FIGURE 2

Tumor growth following treatment with DaRT, TMZ, or the combined treatment. U87-bearing mice (~90 mm3) were treated with a 75-kBq
DaRT seed or inert seed on day 0, followed by nine doses of 1 mg/kg TMZ i.p. on days 1–4 and 6–10. (A) DaRT seed and insertion applicator.
(B) Mean tumor volume ± SEM. The combined treatment signiﬁcantly reduced tumor growth compared to control, DaRT, or TMZ
monotherapies (p < 0.0005, p < 0.0005, p < 0.05). (C). The time to reach ﬁvefold the starting tumor volume was prolonged for animals
receiving DaRT, TMZ, or the combined treatment compared to the control group (p < 0.005, p < 0.05, p < 0.001, respectively).
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TABLE 1 VEGF secretion by U87 cells following alpha irradiation (normalized to % viability).

Dose (Gy)

p-value (vs. control)

VEGF level (pg/ml)

Standard error

0 (control)

1,899.6

421.1

0.7

1,844.3

517.4

0.9

1.4

1,692.1

377.5

0.7

2.8

1,703.0

304.6

0.7

U87 cells were treated with 0.7, 1.4, and 2.8 Gy alpha irradiation and VEGF secretion was determined using the ELISA assay 72 h post-treatment. Secretion was normalized for cell viability.
VEGF concentration is expressed as the mean of three independent experiments. No signiﬁcant enhancement of VEGF secretion was observed.

diameter). Thereafter, each tumor was treated with either a
single DaRT or inert seed. BEV or IgG control treatment
began 5 days post seed insertion. DaRT (n = 13) or BEV (n =
13) as a standalone treatment provided signiﬁcant attenuation in
tumor growth compared to the control (n = 12) group (days 12–
23, p< 0.01–0.0001; days 19–23, p< 0.01–0.0001, respectively).
DaRT-treated tumors were signiﬁcantly smaller compared to the
BEV-treated group (days 14–23, p< 0.05–0.0001). A signiﬁcant
effect on tumor growth was observed in the combined therapy
group (n = 14) compared to BEV (days 12–23 p< 0.05–0.0001),
DaRT alone (days 19–23, p< 0.05), or control (days 12–23, p<
0.001–0.0001) (Figures 3A, B). Twenty-six days after DaRT
insertion, 29% of the tumors in the DaRT+BEV group were
eradicated (4 animals out of a total of 14) and 23% of the tumors

DaRT insertion prior to BEV
administration attenuates tumor
growth of GBM xenografts compared to
either monotherapy
Given the observation that exposure to alpha particles does
not lead to an increase of VEGF secretion in U87 cells, we
hypothesized that the antiangiogenic function of BEV will not
decrease in combination with alpha radiation, allowing
additivity by preventing the potential renewal of GBM tissue
following DaRT-induced ablation. To test the effect of DaRT in
combination with systemic BEV in vivo, two treatment regimens
were used. In the ﬁrst, U87 xenografts were transplanted and
allowed to grow for 9 days to an average size of ~6.5 mm (longest

A

B

C

FIGURE 3

Tumor growth following the combination treatment of DaRT and BEV. U87-bearing mice (~90 mm3) were treated with a 110-kBq DaRT seed or
inert seed on day 0, followed by nine i.p. injections of either BEV or IgG control (5 mg/kg) on days 5, 7, 9, 12, 14, 16, 19, 21, and 23 (three times
per week for three consecutive weeks). Results represent cumulative data of two independent experiments. (A) Tumor volume ± SEM: p< 0.05,
p < 0.05, p < 0.001 for the combined therapy vs. BEV, DaRT, or control, respectively. (B) Representative photographs of one animal from each
treatment group on day 2 and day 23 post DaRT treatment. (C) Percent of tumors that were eradicated in each treatment group. These mice
were followed up for a period of over 3 months, with no recurrence.
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their longest diameter). Such a setting prevents the alphaemitting atoms from covering the entirety of the treated
tumors with therapeutic levels of radiation dose. In this
protocol, BEV administration (same treatment parameters as
in Figure 3) preceded DaRT seed insertion by 4 days. In addition,
the changes in blood vessel structure by BEV in this treatment
protocol were validated four days after DaRT implantation
(activity = 110 kBq, 220Rn desorption probability ~25%) using
CD31 staining. U87 xenografts were transplanted and allowed to
grow to an average size of 6.5 mm (longest diameter) when the
BEV treatment began (see Figure 4). Four days after the ﬁrst
BEV dose, when the average tumor length (longest diameter)
reached ~9 mm, each tumor was treated with either a single
DaRT or an inert seed. Tumor development follow-up ended on
day 26 as some of the tumors were unmeasurable due to
pronounced necrosis. Monitoring tumor growth revealed that
DaRT (n = 5), BEV (n = 5), or the combination treatment (n = 5)
delayed tumor growth compared to control (n = 4) (day 7, p<

in the DaRT-alone group were eradicated (3 animals out of a
total of 13). Tumors that underwent a complete response were
declared as cured as they did not recur for a period of over 3
months from the day of the DaRT treatment (Figure 3C).

Early administration of BEV relative to
DaRT led to a higher effect of the
combination relative to either
monotherapy in larger tumors
The results shown in Figure 3 indicate that in 6- to 7-mm
tumors, the DaRT treatment was the dominant factor affecting
tumor retardation and elimination, and the combination with
BEV signiﬁcantly increased tumor control. To further support a
potential synergy between DaRT and BEV, we used a different
treatment protocol in which a single DaRT seed was inserted
into larger tumors relative to the seed size (~9 mm average in

A

C

B

D

FIGURE 4

Tumor growth following early administration of BEV relative to DaRT. U87-bearing mice were treated with either BEV or IgG control (5 mg/kg)
on days −4 to 14. Four days after the ﬁrst BEV dose, each tumor was treated with either a single 110-kBq DaRT seed or an inert seed. (A) Tumor
volume vs. time (p< 0.005 for the combinational vs. control or vs. each of the monotherapies). (B) Time to reach ﬁvefold of the initial tumor
volume (p < 0.05, combination vs. control). (C) Representative images of CD31 immunohistochemical staining of DaRT-treated U87 tumors
following IgG or BEV (n = 4/group) treatments. Scale bars represent 50 mm. (D) Quantiﬁcation of area percentage of CD31 staining using
ImageJ, showing the mean ± SD of the averaged % of CD31+ region per three representative areas (ROI) in a single specimen. *p < 0.01 DaRT
+IgG vs. DaRT+BEV.
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the contribution of the two alpha particles emitted by 220Rn and
216
Po). The clearance rate of 212Pb is quantiﬁed by its leakage
probability from the tumor. Since BEV affects the tumor
vasculature, its combination with DaRT could modify the
leakage probability of 212Pb, and therefore also its spatial
spread inside the tumor. To investigate this, autoradiography
experiments and measurements of the 212Pb leakage probability
were performed on U87 tumors over a mass range ~0.1–2 g,
where the tumors were treated with a single DaRT seed
combined with either BEV or IgG as control, following the
same treatment regimen employed in the efﬁcacy experiments
described in Figure 4. Figure 5A shows an example of an
autoradiography image of a treated tumor, and Figure 5B
demonstrates an overlay of the estimated 212Bi/212Po dose on
the H&E-stained image of the same section. Figure 5C shows the
dependence of the effective diameter on the tumor mass for the
two groups. While in both groups the effective diameter
increases with the tumor mass, the effective diameter in the
case of DaRT+BEV is, on average, larger by ~0.7 mm compared
to DaRT+IgG for the same tumor mass. A covariance analysis
showed a statistically signiﬁcant difference (p< 0.05) between the
two groups. Figure 5D shows the dependence of the 212Pb
leakage probability on the tumor mass for the two groups. In
the DaRT+BEV group, the leakage probability is on average
smaller by ~25% (in absolute value) compared to the DaRT+IgG

0.05; days 3–10, p< 0.01–0.0005; days 3–10, p< 0.005–0.0001).
BEV reduced tumor growth compared to DaRT (day 10, p<
0.01). The combination treatment showed signiﬁcant growth
delay compared to the DaRT or BEV (days 3–10, p< 0.05–
0.0001; day 10, p< 0.005; respectively) alone (Figure 4A). The
time to reach ﬁvefold the initial tumor volume was increased in
the combined treatment vs. DaRT, BEV, or control (p< 0.05)
(Figure 4B). A signiﬁcant reduction in CD31 staining (p< 0.01)
validated the effect of BEV on the DaRT-treated blood vessels
(Figures 4C, D). Notably, one out of the ﬁve animals treated with
DaRT+BEV experienced a complete eradication of the tumor.
This phenomenon was not recorded in other treatment groups.

BEV increases the spread of alpha
emitters in the tumor by reducing the
clearance of 212Pb through the blood
As discussed in (32), the physics model of DaRT predicts
that the spread of 212Pb inside the tumor decreases with
increasing rate of its clearance through the blood. Here, we
quantiﬁed the spread by the effective diameter of the region in
which the local measured 212Pb activity translated to an
estimated macroscopic alpha dose of >10 Gy by the alpha
emissions of 212Bi and 212Po (note that this does not include

A

C

E

B

D

F

FIGURE 5

Effect of BEV on the intra-tumoral spread of 212Pb and its clearance from the tumor through the blood. (A) A typical autoradiography image of
a U87 tumor treated by a single DaRT seed, in raw photo-stimulated luminescence (PSL) units. (B) Same tumor section, with the PSL map
translated to estimated dose, overlaid on an image of the H&E-stained section. (C) Effective diameter of the region subject to an estimated
macroscopic 212Bi/212Po alpha dose of >10 Gy as a function of the tumor mass, for tumors treated by DaRT+BEV and by DaRT+IgG as control.
(D) The 212Pb leakage probability as a function of the tumor mass for the DaRT+BEV/IgG groups. (E, F) Correlation between the effective
diameter and 212Pb leakage probability for the two groups.
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more tumor cells are exposed to a lethal dose of alpha particles. A
second possibility is that adding BEV to DaRT may reduce tumor
regrowth by decreasing the vessel density and blood supply to
surviving tumor cells and to potential glioma stem cell niches (60),
thereby diminishing their re-establishment after the DaRT
treatment. BEV administration may have also led to reduced
interstitial pressure by reducing vessel leakiness (61). This could
have assisted tumor shrinkage, bringing peripheral tumor cells
closer to the seed. In addition, interstitial pressure within tumors
is known to compromise drug extravasation across the capillary
walls (62). It is yet unknown what is the effect of DaRT on the
tumor microenvironment and whether it affects the availability of
drugs such as TMZ or BEV to the tumor tissue. These questions
should be further investigated in subsequent studies.
Traditional brachytherapy in the brain may lead to adverse
effects such as intracranial arterial occlusion (63), hemorrhage, and
radiation necrosis (64). Recently, 131Cs (half-life of 9.7 days) seeds,
emitting ~30- keV x-rays, have received FDA clearance for brain
tumors (65). It was suggested that this isotope would lead to less
radionecrosis relative to 125I-based brachytherapy (66), whose 59day half-life is considered a risk factor for late-stage adverse effects
(66). The safety proﬁle of DaRT in the brain is yet to be
demonstrated. Nevertheless, several advantages of using DaRT
may be expected: (1) the dose ﬁeld is characterized by a rapid
fall-off, dropping to negligible levels ~2–3 mm away from the
outermost seeds, offering improved sparing of adjacent healthy
brain tissue; (2) the cell-killing ability of alpha particles is largely
unaffected by hypoxia, unlike low-LET radiation; (3) the half-life of
244
Ra is relatively short (3.6 days), and thus, following radiation
delivery, fewer late complications are anticipated; (4) DaRT does
not counteract standard-of-care treatments, for example, by
increasing VEGF secretion that may reduce the efﬁciency of BEV
and enhance recurrence after treatment; furthermore, the present
study even provides evidence that DaRT potentially synergizes
with standard-of-care drugs, in particular with BEV. Thus, adding
DaRT to such systemic therapies could potentially further delay the
disease progression and extend the patient lifespan.
The presence of highly inﬁltrative cancer stem cells, in the
peritumoral region of GBM, appears to play a key role in tumor
growing and recurrence (67). High-LET radiation was
previously shown to overcome radioresistance of glioma stemlike cells to low-LET radiation (68). Thus, it may be suggested
that using DaRT for the treatment of the invasive region around
the main tumor mass following tumor resection may have
advantage in both efﬁcacy and safety compared to low-LETbased therapies due to potential reduced radioresistance and the
localized nature of the treatment, with minimal damage to
adjacent tissue. Compared to targeted alpha therapy for GBM,
delivered by intratumoral or intracavity injection, DaRT has the
advantage of providing controlled geometric coverage of the
target volume, using dedicated applicators (which are presently
under development) for deploying multiple seeds through a
single entry point in the skull. This can allow avoiding

group, with a statistical signiﬁcance of p< 0.0005. The effective
diameter was negatively correlated with the leakage from the
tumor in both groups (Figures 5E, F, p< 0.005).

Discussion
The current study demonstrated a superior effect of DaRT in
combination with standard-of-care drugs (TMZ and BEV) in
mice-bearing GBM xenografts, relative to the effect of the singletreatment modalities. As a ﬁrst step, we examined the direct
effect of the standard chemotherapy, TMZ, in combination with
alpha-particle irradiation on U87 cells. One could expect that the
combination treatment would yield a lower cytotoxic effect than
the sum of the monotherapies, due to a subpopulation of cells
affected by both TMZ and alpha particles. Nevertheless, alpha
irradiation in combination with TMZ was actually shown to
double the cytotoxic effect of each of the monotherapies on U87
cells in culture. This may suggest that for cells that would have
otherwise received a sublethal dose of either TMZ or alpha
irradiation and survived these monotherapies, the DNA breaks
caused by the combination of TMZ (55, 56), together with the
complex DNA damage produced by alpha particles (57), lead to
unrecoverable damage to the DNA. In addition, this
combination was advantageous compared to the combination
of TMZ and x-rays as demonstrated by the lower surviving
fraction in a colony formation assay. Finally, the enhanced
tumor control of the combination treatment in GBM
xenografts supported these observations and showed a
superiority of combining DaRT with TMZ in vivo.
The previously reported ability of x-ray irradiation to
upregulate VEGF expression and secretion in GBM cells (12–14)
was not observed following alpha-particle irradiation. This may
support using DaRT in combination with VEGF inhibition and
may indicate that the DNA damage induced by alpha particles is
unlinked to HIF-1-induced VEGF transcription (58, 59).
In the current study, two treatment regimens were used to
evaluate the combination of DaRT and BEV in vivo. It was shown
that when a single DaRT seed was used in a standard experimental
protocol in relatively small tumors, in which the seed length was
similar to the tumor’s longest diameter, the DaRT treatment was
the main factor retarding tumor growth, whereas in relatively
large tumors, where it would have been expected that a single
DaRT seed would be less effective, the introduction of the BEV
treatment prior to DaRT insertion yielded a pronounced effect of
the combination treatment compared to both monotherapies, and
a clear interaction between the treatments was demonstrated.
The underlying mechanism for this apparent synergy is not yet
understood, and may, in fact, combine several complementary
effects. First, the observation that BEV enhances the spatial
spread of 224Ra progeny atoms, expressed by the effective
diameter, inside the tumor and reduces the leakage of 212Pb into
the bloodstream, may indicate a simple physical explanation, where
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uncertainties associated with catheter-based delivery, where
drug spillage to healthy regions may greatly reduce the efﬁcacy
of the treatment and increase the risk for brain tissue toxicity.
Improving the survival of GBM patients presents an
enormous challenge and an unmet need that requires the
addition of novel therapeutic strategies to the clinical toolbox.
Overall, the results in this study demonstrate the potential
beneﬁt of alpha radiation-based local radiotherapy in
combination with drugs routinely used for GBM treatment in
clinical settings, and support testing DaRT as a therapeutic tool
in clinical trials for patients with GBM.
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